Amit R. Nayak

Amit R. Nayak

Auto-generated profile, based on publicly available information

Amit R. Nayak

Advanced Research Centre, Central India Institute of Medical Sciences, Nagpur-10, Maharashtra, India

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2016 in Annals of Neurosciences
Verified
Journal Article
Open access
PDF file
ANAmit R. Nayak
Amit R. Nayak
SBShweta R. Badar
Shweta R. Badar
NLNeha Lande
Neha Lande
AKAnuja P. Kawle
Anuja P. Kawle
DKDinesh P. Kabra
Dinesh P. Kabra
RKRajpal S. Kashyap
Rajpal S. Kashyap
Background: Demographic and clinical characteristics are known to influence the outcome in acute ischemic stroke (AIS) patients. Purpose: This study is aimed at evaluating short- and long-term outcomes in diabetic AIS patients. In addition, the study also evaluates the impact of diabetes on the performance of indigenously reported biomarker, inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) and known biomarkers, neuron-specific enolase (NSE) and glial-derived S-100 beta beta protein (S-100ββ). Methods: This study was performed on 29 diabetes and 75 non-diabetes AIS patients. Outcome of AIS patients was analyzed by using modified Rankin scale at discharge, then at 12 and 18 months after discharge. Based on the obtained scores, patients were classified as improved group (scales 1-3) and dependent/expired group (scales 3-6). Blood samples were collected during admission and at discharge/expired time. Levels of NSE, S100ββ, and ITIH4 were analyzed in all samples. Results: On discharge, frequencies of dependent/expired outcome were 4/29 (14%) and 19/75 (17%) in diabetic and non-diabetic AIS patients. However, follow-up outcome at 12 and 18 months showed higher dependent/expired cases of 43 and 41% among diabetic AIS patients compared to 27 and 21% in non-diabetic patients. Multivariate analysis revealed that diabetes is an independent risk factor for dependent/expired outcome in AIS patients (OR 0.484 (at discharge); 1.307 (at 12 months) and 1.675 (at 18 months)). NSE, S100ββ, and ITIH4 showed a differential expression in both the outcome groups of AIS patients, irrespective of diabetes. Conclusion: Diabetes increases the risk of dependent/expired outcome in AIS patients. Also, serum NSE, S100ββ, and ITIH4 are independent biomarkers for prognosis of outcome in AIS patients, irrespective of diabetes.

16 September 2015 in International Journal of Peptide Research and Therapeutics
Verified
Journal Article
Open access
PDF file
AHAliabbas A. Husain
Aliabbas A. Husain
HDHatim F. Daginawala
Hatim F. Daginawala
SWShubhangi R. Warke
Shubhangi R. Warke
DKDewanand R. Kalorey
Dewanand R. Kalorey
NKNitin V. Kurkure
Nitin V. Kurkure
RKRajpal S. Kashyap
Rajpal S. Kashyap
Limited experimental evidences are available on the use of peptides as vaccines to boost BCG induced immunity for protection against tuberculosis. The present study therefore evaluated protective efficacy of booster dose of N-terminal peptides of Ag85B, using prime boost approaches in murine model of tuberculosis. Using earlier established subcutaneous murine model of TB in our laboratory, we compared the protective vaccination efficacy of peptides of Ag85B with that of booster dose of whole Ag85B and BCG by evaluating both antibody and cell-mediated immune response. Groups of mice primed by BCG and boosted with Ag85B peptides showed limited pulmonary bacillary burden and reduced lung pathology after challenge with virulent dose of Mycobacterium tuberculosis in mice. Significant levels (p < 0.001) of BCG specific antibodies (anti-BCG, anti-PPD) and T cell-specific cytokines were observed in Ag85B peptides boosted mice compared to Ag85B and BCG. Ag85B and BCG boosted mice however showed significant protection compared to single BCG dose and unvaccinated control groups. Our result suggests that prime boost strategy using N-terminal peptides of Ag85B may improve immunogenicity of BCG against TB. Such peptides may be attractive candidates for boosting waning BCG induced immune response in near future. However study demands further work including improvisation in experimental designs to justify the results.

24 January 2025 in Research Square
Verified
Preprint
Open access
PDF file
ANAmit R Nayak
Amit R Nayak
AHAliabbas Husain
Aliabbas Husain
JBJawad Baksh
Jawad Baksh
DKDewanand R. Kalorey
Dewanand R. Kalorey
NKNitin Kurkurey
Nitin Kurkurey
RKRajpal S Kashyap
Rajpal S Kashyap
This study aimed to develop a cost-effective middle cerebral artery occlusion (MCAO) model in rats using an intraluminal suture method with a magnifying glass lens, an alternative to a surgical microscope. Male Sprague-Dawley rats underwent MCAO surgery, and neurological deficits were assessed post-surgery. Neurological scores were significantly higher in MCAO rats (mean score 3.5 ± 0.5) compared to sham-operated controls (mean score 0.5 ± 0.2) (p < 0.001). 2,3,5-Triphenyltetrazolium chloride (TTC) staining revealed significant infarction in the ischemic region (mean infarct volume 45.2 ± 5.6%), while no infarct was observed in sham-operated controls (0%). Histopathological analysis confirmed ischemic damage, and immunofluorescence staining showed reduced NeuN (62.4% ± 8.2%) and GFAP (70.3% ± 7.5%) expression in the ischemic cortex compared to sham (p < 0.01). Brain water content was significantly higher in the ischemic hemisphere (82.5% ± 2.1%) compared to the contralateral hemisphere (78.4% ± 1.3%) (p < 0.05). The magnifying glass lens-based technique provided a reliable, cost-effective alternative for MCAO surgery, maintaining high reproducibility. This model can be used for preclinical stroke research, neuroprotective studies, and investigating ischemic pathophysiology, especially in resource-limited settings. Overall, the magnifying glass lens MCAO model proves to be an effective tool for stroke research and translational studies in low-resource environments.

2 June 2022 in medRxiv
Verified
Preprint
Open access
PDF file
ANAmit R. Nayak
Amit R. Nayak
SMSwapnil S. Muley
Swapnil S. Muley
RKRajpal S. Kashyap
Rajpal S. Kashyap
NLNeha H. Lande
Neha H. Lande
DKDinesh P. Kabra
Dinesh P. Kabra
HDHatim F. Daginawala
Hatim F. Daginawala
Purpose: MMP-9 is reported to be a marker of severity and worse outcome after stroke. Despite the above information, there are very few studies based on the evaluation of role of follow-up estimation of serum MMP-9 in acute ischemic stroke (AIS) patients. The purpose of this study was to evaluate the role of follow-up estimation of serum MMP-9 in the prognosis of AIS patients. MMP-9 levels were also compared with reported biomarkers viz. Neuron-Specific Enolase (NSE), Glial specific protein (S100ββ) and Inter-α-trypsin inhibitor heavy chain 4 (ITIH4). Materials/methods: MMP-9, NSE, and S-100ββ were measured in serum samples collected at admission and expired/discharge time of AIS patients (n=48) using commercially available ELISA kits. ITIH4 was measured using Indirect ELISA protocol. Results: MMP-9 at admission (3639 ±1471) and discharged/expired (3707 ±1268) was significantly higher (p<0.05) in AIS patients as compared to healthy control subjects (749 ±302). Expired patients showed significantly (p<0.05) higher MMP-9 as compared to survivors. Similarly, follow-up MMP-9 at discharge was higher in AIS patients who expired within one year (75%; 3/4). The observed values of MMP-9 significantly correlates (p<0.05) with NSE (r=0.452), S-100ββ (r=0.452) and ITIH4 (r=-0.2027). Conclusions: Follow-up measurement of serum MMP-9 may help to predict both short term and long term mortality in AIS patients.

20 September 2026 in Journal of Ayurveda and Integrated Medical Sciences
Verified
Journal Article
Open access
PDF file
PDPrachi Dabhade
Prachi Dabhade
ANAkshata Nandanwar
Akshata Nandanwar
ANAmit Nayak
Amit Nayak
AHAliabbas Husain
Aliabbas Husain
NBNandini Bhojraj
Nandini Bhojraj
RKRajpal Singh Kashyap
Rajpal Singh Kashyap
The global rise in anti-microbial resistance with the limited bioavailability and suboptimal pharmacokinetic performance of conventional therapeutics, it has intensified the interest in natural bioenhancer capable of improving therapeutics, having intensified the interest in natural bioenhancer thus capable of improving therapeutic efficacy across infectious and non-infectious disease settings. Cow urine distillate (CUD), an Ayurvedic preparation, has showcased the immunomodulatory, anti-inflammatory, antimicrobial, and bioavailability-enhancing properties. The in-silico investigation explored CUD-derived bioactive constituents as a multi-target bioenhancer, having its key role on vivid and diverse molecular pathways that act in fungal, parasitic, bacterial, viral, inflammatory, and immune-mediated disorders. Computational studies have revealed the CUD phytochemicals and key pathogen targets, like penicillin-binding protein 2a (PBP2a), topoisomerase IV, viral proteases, β-tubulin, and glutathione S-transferase, RNA-dependent RNA polymerase, lanosterol 14-α-demethylase (CYP51), host-regulatory targets such as cyclooxygenase-2 (COX-2), nuclear factor-κB (NF-κB), and Toll-like receptors. Literature suggests that primary constituents, including cinnamic acid, ferulic acid, indole, and hexanoic acid, are evaluated by in silico tools like AutoDock Vina, MOE, and Schrödinger Glide, Molecular Dynamics (MD) simulations to assess binding stability and conformational behavior. Molecular Docking results are indicative of stable binding affinities and in silico ADMET analyses by using SwissADME and pkCSM, predicting favorable oral bioavailability and low toxicity profiles compatible with adjunctive use. Network pharmacology analyses support a polypharmacological mode of action targeting both pathogen survival pathways and host immune-inflammatory signaling. The available in silico evidence proves CUD as a promising multi-target bioenhancer; systematic in vitro and in vivo validation are essential to substantiate its translational potential.

12 August 2026 in Journal of Ayurveda and Integrated Medical Sciences
Verified
Journal Article
Open access
PDF file
PDPrachi Dabhade
Prachi Dabhade
ANAkshata Nandanwar
Akshata Nandanwar
ANAmit Nayak
Amit Nayak
AHAliabbas Husain
Aliabbas Husain
NBNandini Bhojraj
Nandini Bhojraj
RKRajpal Singh Kashyap
Rajpal Singh Kashyap
Cancer poses a significant global health burden, aligning conventional therapies limited by poor drug bioavailability, systemic toxicity, and the development of chemoresistance. The aligning challenges have showcased the growing interest in natural bioenhancers, which are capable of improving therapeutic efficacy while mitigating adverse effects. Cow urine distillate (CUD), a traditional Ayurvedic preparation that is derived from Bos indicus, holds impressive research data in terms of immunomodulatory, antioxidant, and bioavailability-enhancing properties. CUD constitutes phytochemicals like ferulic acid, cinnamic acid, and phenylethanol, and cinnamic acid shows favorable binding affinities in docking studies performed with in silico tools like AutoDock Vina, Schrödinger Glide, and Molecular Operating Environment. As the research literature indicates, molecular dynamics simulations show a stable ligand receptor with reported minimal conformational fluctuation. The in silico investigations has revealed the potential of CUD derived phytochemicals as adjuvants in oncology with the primary cancer associated molecular targets including Cyclin dependent kinases, DNA topoisomerase II, epidermal growth factor receptor (EGFR), phosphoinositide 3-kinase (PI3K), vascular endothelial growth factor receptor (VEGFR), protein kinase B (Akt), Bcl-2, and matrix metalloproteinases are widely researched and explored using high-resolution structures from the Protein Data Bank. In silico ADMET profiling ensured by SwissADME and pkCSM gives good oral absorption, drug-likeness, and low predicted toxicity, supporting translational feasibility. Network pharmacology analyses have reported multi-target modulation of pathways controlling apoptosis, proliferation, angiogenesis, inflammation, immune response, and therapeutic resistance. Computational insights give the rationale for the mechanism for CUD as a multitarget natural bioenhancer. Showing the need for systematic in vitro, in vivo, and clinical studies to validate its bioenhancing and adjunctive potential in cancer therapeutics.